Form 4: Adverum Biotechnologies Executive Acquires Stock Options
SEC Form 4 Filing
Setareh Seyedkazemi, Chief Development Officer of Adverum Biotechnologies, acquired 43,458 stock options on August 2, 2024.
Summary
- On August 2, 2024, Setareh Seyedkazemi, the Chief Development Officer of Adverum Biotechnologies, acquired 43,458 stock options.
- The options have an exercise price of $7.15.
- The options vest over three years, starting August 2, 2024, with one-third vesting on the first anniversary and the remainder vesting monthly thereafter.
- Following the transaction, Seyedkazemi directly owns 43,458 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard Form 4 filing indicating stock option acquisition. It could be interpreted as slightly positive due to the executive's increased stake in the company, but it's not definitively bullish.
Positives
- The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates activity by a key executive at Adverum Biotechnologies.
Stakeholder Impact
- The acquisition of stock options by a key executive could potentially increase shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 08/02/2024 | Date of the stock option transaction. |
| 08/02/2024 | Vesting Commencement Date. |
| 08/01/2034 | Expiration date of the stock options. |
| 08/06/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.